We serve Chemical Name:5-amino-1-(3-chlorophenyl)pyrazole-4-carboxamide CAS:50427-78-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-amino-1-(3-chlorophenyl)pyrazole-4-carboxamide
CAS.NO:50427-78-6
Synonyms:f2135-0889
Molecular Formula:C10H9ClN4O
Molecular Weight:236.65800
HS Code:2933199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:459ºC at 760 mmHg
Density:1.55g/cm3
Index of Refraction:1.715
PSA:87.92000
Exact Mass:236.04600
LogP:2.67220
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like f2135-0889 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,f2135-0889 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,f2135-0889 Use and application,f2135-0889 technical grade,usp/ep/jp grade.
Related News: Like other countries in Southeast Asia, Indonesia depends heavily on Chinese tourism. On Thursday alone, 10,000 Chinese tourists canceled their trips to Bali, according to one industry association. 5-amino-1-(3-chlorophenyl)pyrazole-4-carboxamide manufacturer The Branchburg factory first came under FDA scrutiny in late 2019, when agency inspectors began to document numerous quality control problems. By March, 2020, the FDA had deemed the manufacturing issues as “Official Action Indicated,” its most serious category of violation. 5-amino-1-(3-chlorophenyl)pyrazole-4-carboxamide supplier Like other countries in Southeast Asia, Indonesia depends heavily on Chinese tourism. On Thursday alone, 10,000 Chinese tourists canceled their trips to Bali, according to one industry association. 5-amino-1-(3-chlorophenyl)pyrazole-4-carboxamide vendor The Branchburg factory first came under FDA scrutiny in late 2019, when agency inspectors began to document numerous quality control problems. By March, 2020, the FDA had deemed the manufacturing issues as “Official Action Indicated,” its most serious category of violation. 5-amino-1-(3-chlorophenyl)pyrazole-4-carboxamide factory Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.
